Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

76 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
HDAC6 as a Prognostic Factor and Druggable Target in HER2-Positive Breast Cancer.
Cortesi M, Bravaccini S, Ravaioli S, Petracci E, Angeli D, Tumedei MM, Balzi W, Pirini F, Zanoni M, Possanzini P, Rocca A, Palleschi M, Ulivi P, Martinelli G, Maltoni R. Cortesi M, et al. Among authors: palleschi m. Cancers (Basel). 2024 Nov 6;16(22):3752. doi: 10.3390/cancers16223752. Cancers (Basel). 2024. PMID: 39594707 Free PMC article.
Dissecting Molecular Heterogeneity of Circulating Tumor Cells (CTCs) from Metastatic Breast Cancer Patients through Copy Number Aberration (CNA) and Single Nucleotide Variant (SNV) Single Cell Analysis.
Rossi T, Angeli D, Tebaldi M, Fici P, Rossi E, Rocca A, Palleschi M, Maltoni R, Martinelli G, Fabbri F, Gallerani G. Rossi T, et al. Among authors: palleschi m. Cancers (Basel). 2022 Aug 14;14(16):3925. doi: 10.3390/cancers14163925. Cancers (Basel). 2022. PMID: 36010918 Free PMC article.
Are we ready to use TMB in breast cancer clinical practice?
Ravaioli S, Limarzi F, Tumedei MM, Palleschi M, Maltoni R, Bravaccini S. Ravaioli S, et al. Among authors: palleschi m. Cancer Immunol Immunother. 2020 Oct;69(10):1943-1945. doi: 10.1007/s00262-020-02682-w. Epub 2020 Jul 28. Cancer Immunol Immunother. 2020. PMID: 32725361 Free PMC article.
Ki67 and PR in Patients Treated with CDK4/6 Inhibitors: A Real-World Experience.
Palleschi M, Maltoni R, Ravaioli S, Vagheggini A, Mannozzi F, Fanini F, Pirini F, Tumedei MM, Barzotti E, Cecconetto L, Sarti S, Manunta S, Possanzini P, Fedeli A, Curcio A, Altini M, De Giorgi U, Rocca A, Bravaccini S. Palleschi M, et al. Diagnostics (Basel). 2020 Aug 8;10(8):573. doi: 10.3390/diagnostics10080573. Diagnostics (Basel). 2020. PMID: 32784518 Free PMC article.
An Italian Real-World Study Highlights the Importance of Some Clinicopathological Characteristics Useful in Identifying Metastatic Breast Cancer Patients Resistant to CDK4/6 Inhibitors and Hormone Therapy.
Maltoni R, Roncadori A, Balzi W, Mazza M, Nicolini F, Palleschi M, Ulivi P, Bravaccini S. Maltoni R, et al. Among authors: palleschi m. Biomedicines. 2024 Feb 22;12(3):498. doi: 10.3390/biomedicines12030498. Biomedicines. 2024. PMID: 38540112 Free PMC article.
Precision medicine: PI3K targeting in advanced breast cancer.
Rocca A, Melegari E, Palleschi M. Rocca A, et al. Among authors: palleschi m. Breast Cancer Res Treat. 2019 Nov;178(2):479. doi: 10.1007/s10549-019-05409-3. Epub 2019 Aug 19. Breast Cancer Res Treat. 2019. PMID: 31428907 Free article. No abstract available.
76 results